These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 7820614)

  • 1. Cholecystokinin octapeptide (CCK-8) antagonizes morphine analgesia in nucleus accumbens of the rat via the CCK-B receptor.
    Pu SF; Zhuang HX; Han JS
    Brain Res; 1994 Sep; 657(1-2):159-64. PubMed ID: 7820614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cholecystokinin octapeptide (CCK-8) antagonizes morphine analgesia in amygdala of the rat].
    Pu SF; Han JS
    Sheng Li Xue Bao; 1993 Oct; 45(5):470-8. PubMed ID: 8146670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased release of immunoreactive cholecystokinin octapeptide by morphine and potentiation of mu-opioid analgesia by CCKB receptor antagonist L-365,260 in rat spinal cord.
    Zhou Y; Sun YH; Zhang ZW; Han JS
    Eur J Pharmacol; 1993 Apr; 234(2-3):147-54. PubMed ID: 8387008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antagonistic effect of CCK-8 on morphine-inhibited electrical and contractile activities of rat jejunum in vitro.
    Xu MY; Yang DX; Wang SZ; Jin HB; Zou XH; Yang XP; Han JS
    Sheng Li Xue Bao; 1998 Aug; 50(4):469-73. PubMed ID: 11324560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholecystokinin increases extracellular dopamine overflow in the anterior nucleus accumbens via CCK(B) receptors in the VTA assessed by in vivo voltammetry.
    Reum T; Schäfer U; Marsden CA; Fink H; Morgenstern R
    Neuropeptides; 1997 Feb; 31(1):82-8. PubMed ID: 9574843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Potentiation of morphine- and ohmefentanyl-induced analgesia by cholecystokinin receptor antagonists in rat].
    Zhou Y; Sun YH; Han JS
    Sheng Li Xue Bao; 1993 Jun; 45(3):255-61. PubMed ID: 8235725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of cholecystokinin octapeptide-stimulated endogenous dopamine release from rat nucleus accumbens in vitro.
    Marshall FH; Barnes S; Pinnock RD; Hughes J
    Br J Pharmacol; 1990 Apr; 99(4):845-8. PubMed ID: 2361176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subtype-selective cholecystokinin receptor antagonists block cholecystokinin modulation of dopamine-mediated behaviors in the rat mesolimbic pathway.
    Crawley JN
    J Neurosci; 1992 Sep; 12(9):3380-91. PubMed ID: 1527584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholecystokinin octapeptide induces endogenous opioid-dependent anxiolytic effects in morphine-withdrawal rats.
    Wen D; Sun D; Zang G; Hao L; Liu X; Yu F; Ma C; Cong B
    Neuroscience; 2014 Sep; 277():14-25. PubMed ID: 24993476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individual differences in the feeding response to CCKB antagonists: role of the nucleus accumbens.
    Sills TL; Vaccarino FJ
    Peptides; 1996; 17(4):593-9. PubMed ID: 8804067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The antagonistic effect of cholecystokinin octapeptide (CCK-8) on opioid effects in cardiovascular activities was mediated by CCK-B receptor.
    Mei L; Han JS
    Sci China B; 1993 Jul; 36(7):817-23. PubMed ID: 8216742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of spinal cholecystokininB receptors in mediating neurotensin hyperalgesia from the medullary nucleus raphe magnus in the rat.
    Urban MO; Smith DJ; Gebhart GF
    J Pharmacol Exp Ther; 1996 Jul; 278(1):90-6. PubMed ID: 8764339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholecystokinin (CCK) increases GABA release in the rat anterior nucleus accumbens via CCK(B) receptors located on glutamatergic interneurons.
    Lanza M; Makovec F
    Naunyn Schmiedebergs Arch Pharmacol; 2000 Jan; 361(1):33-8. PubMed ID: 10651144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholecystokinin modulates the release of dopamine from the anterior and posterior nucleus accumbens by two different mechanisms.
    Marshall FH; Barnes S; Hughes J; Woodruff GN; Hunter JC
    J Neurochem; 1991 Mar; 56(3):917-22. PubMed ID: 1993898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Receptor selectivity of cholecystokinin effects on mesoaccumbens dopamine neurons.
    Kelland MD; Zhang J; Chiodo LA; Freeman AS
    Synapse; 1991 Jun; 8(2):137-43. PubMed ID: 1882334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholecystokinin potentiates morphine anticonvulsant action through both CCK-A and CCK-B receptors.
    Legido A; Adler MW; Karkanias C; Geller EB; Bradley E; Greenstein JI; Grover WD
    Neuropeptides; 1995 Feb; 28(2):107-13. PubMed ID: 7746354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The CCK-A and CCK-B receptor antagonists, devazepide and L-365,260, enhance morphine antinociception only in non-acclimated rats exposed to a novel environment.
    Lavigne GJ; Millington WR; Mueller GP
    Neuropeptides; 1992 Feb; 21(2):119-29. PubMed ID: 1557183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for potentiation by CCK antagonists of the effect of cholecystokinin octapeptide in the elevated plus-maze.
    Vasar E; Lang A; Harro J; Bourin M; Bradwejn J
    Neuropharmacology; 1994 Jun; 33(6):729-35. PubMed ID: 7936110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology of a cholecystokinin receptor on 5-hydroxytryptamine neurones in the dorsal raphe of the rat brain.
    Boden PR; Woodruff GN; Pinnock RD
    Br J Pharmacol; 1991 Mar; 102(3):635-8. PubMed ID: 1364831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different modifications of the dopamine metabolism in the core and shell parts of the nucleus accumbens following CCK-A receptor stimulation in the shell region.
    Ladurelle N; Durieux C; Roques BP; Daugé V
    Neurosci Lett; 1994 Aug; 178(1):5-10. PubMed ID: 7816338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.